{"Symbol": "ALDX", "AssetType": "Common Stock", "Name": "Aldeyra The", "Description": "Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.", "CIK": "1341235", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "131 HARTWELL AVENUE, LEXINGTON, MA, UNITED STATES, 02421", "OfficialSite": "https://www.aldeyra.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "317659000", "EBITDA": "-44923856", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.819", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.73", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.289", "ReturnOnEquityTTM": "-0.643", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.73", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "9.67", "AnalystRatingStrongBuy": "1", "AnalystRatingBuy": "4", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "6.46", "EVToRevenue": "-", "EVToEBITDA": "-3.498", "Beta": "0.964", "52WeekHigh": "7.2", "52WeekLow": "1.14", "50DayMovingAverage": "4.937", "200DayMovingAverage": "4.602", "SharesOutstanding": "60163000", "SharesFloat": "47577900", "PercentInsiders": "3.086", "PercentInstitutions": "66.351", "DividendDate": "None", "ExDividendDate": "None"}